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Malignant gliomas, comprising the majority of primary brain
tumours in adults, have a very poor prognosis. Traditional thera-
pies, such as surgery, radiotherapy and some chemotherapeutic
agents, have been used in various combinations in the search for a
curative regimen. Radiotherapy has a major role in the adjuvant
therapies for malignant gliomas. Despite notable technical
advances in both the surgical and radiotherapeutic treatment
approaches to malignant gliomas during the last decade, patient
survival has not improved. The presence of hypoxic tumour cells
is thought to be a major reason for tumour resistance to radio-
therapy (Gray et al, 1953; Hall, 1994).
Molecular oxygen has long been recognized as one of the most
powerful modifiers of cellular radiation sensitivity. For example,
oxygen has been reported to increase, by a factor of approximately
3, the biological effect of ionizing radiation on mammalian cells in
which radiation is performed under well-oxygenated conditions as
compared to anoxic conditions (Gray et al, 1953). Thus hyperbaric
oxygen (HBO) exposure, which improves the oxygen supply to
hypoxic tumour cells, was used in combination with radiotherapy
to treat malignant gliomas (Chang, 1977; Dowling et al, 1992).
The previous combination method in which irradiation was admin-
istered during HBO exposure was hazardous to patients and a
complex technique, and as a result HBO has not been routinely
adopted with radiotherapy to treat malignant gliomas (Chang,
1977; Jain, 1990; Dische, 1991).
Exposure to HBO produces tissue oxygenation, and the
increased  PO2 persists in normal tissues for certain periods after
decompression (Wells et al, 1977). We hypothesized that if PO2 in
malignant gliomas remains elevated after HBO exposure, the
resulting improvement in irradiation after decompression may lead
to enhanced tumour control. In our previous pilot study, we
reported that all patients who received HBO experienced regres-
sion of their residual tumours (Kohshi et al, 1996). Consequently,
we evaluated the effectiveness and safety of this new approach to
treat malignant gliomas.
MATERIALS AND METHODS
Patient selection
At our University Hospital of Occupational and Environmental
Health between 1987 and 1997, and at Amakusa Medical Center
between 1990 and 1997, 72 cases with newly diagnosed malignant
gliomas were locally irradiated after tumour debulking or biopsy.
Patients have been consecutively treated by radiotherapy
combined with HBO at the above two institutions since 1991 and
1993 respectively. Eligibility criteria included:
1. all patients were above the age of 16 years
2. anaplastic astrocytoma or glioblastoma multiforme was
pathologically verified according to the World Health
Organization classification (Kleihues et al, 1993)
3. measurable disease was exhibited on pre-treatment contrast-
enhanced computerized tomography (CT) or magnetic
resonance imaging (MRI) scan
4. Karnofsky Performance Scale (KPS) score was 60 or greater
at the time of assignment (Karnofsky et al, 1948)
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5. patients treated with HBO had no cardiopulmonary diseases or
sinusitis.
Patients were excluded if they had no residual tumour. Eligible
patients were not to have received any previous radiotherapy or
chemotherapy, but conventional doses of corticosteroids and anti-
convulsants were allowed. Informed consent was obtained from
all patients.
Protocol
Radiotherapy began within 2 weeks after surgery in conjunction
with chemotherapy as prescribed below. The irradiated field was
determined by defining the volume of the tumour on CT or MRI
scans prior to initiation of radiotherapy and allowing for a margin
of at least 2 cm, but sparing as much brain as possible. External-
beam radiotherapy was performed, using 10 MV X-rays from
linear accelerators with a total dose of 50–71 Gy in 20–30 frac-
tions, for 5 days per week over 5–6 weeks. To determine the effec-
tiveness of the dose on the tumour, the biologically effective dose
(BED) was calculated according to the guidelines of Fowler
(Fowler, 1989) and were expressed in units of 10 Gy, using an a–b
of 10, according to the formula: BED = total dose ´ (1 + fraction
dose/a–b). Exposure to HBO was administered in hyperbaric
chambers according to the following schedule: 15 min of
compression with air, 60 min of 100% oxygen inhalation using an
oxygen mask at 2.5 atmospheres absolute and 10 min of decom-
pression with oxygen inhalation. Each irradiation was adminis-
tered daily after HBO exposure. The periods of time from
decompression to irradiation were different in the two institu-
tions, and were within 15 and 30 min after decompression.
Corticosteroids were used perioperatively, during an early phase
of radiotherapy, and as necessary thereafter. Supportive
chemotherapy was performed in all patients and was similar for
the two treatment groups. All patients were given nitrosourea as
nimustine or ranimustine intravenously at a dose of 75 mg m-2.
The first dose was scheduled for the beginning of the radiotherapy
and the second dose was administered 5 or 6 weeks later. Some
patients in each treatment group received administration of
interferon-b.
Evaluation of response and statistical analysis
Clinical and neuroimaging follow-up evaluations were obtained
for all patients 2–76 months after the completion of radiotherapy.
CT and/or MRI scans were performed every 3 months for 1 year
after radiotherapy, and then at 6-month intervals thereafter as indi-
cated. The neurological status and the occurrence of complications
were monitored in all patients. We estimated the amount of mass
reduction by comparing contrast-enhanced CT or MRI scans
obtained immediately after surgery with those obtained periodi-
cally after the completion of radiotherapy. The tumour size was
defined for this study as the area of enhancing mass lesion, and
was measured as the lesion size in the product of perpendicular
diameters of each slice. The product of these values was calculated
to provide an approximation of tumour area. Although this value is
not an accurate measure of absolute tumour volume, it is adequate
for use in comparing relative size from different scans from the
same patient. Complete response was defined as the disappearance
of all visible tumour. Partial response was defined as at least 50%
regression of the tumour. No response was considered as less than
50% regression or progression of the contrast-enhanced mass.
Complete and partial responses were defined as indications of
effective treatment, and the ‘response rate’ was calculated as the
percentage of cases with complete and partial responses. Tumour
recurrence was defined as progression after partial or complete
response.
We investigated the differences in patient characteristics and
treatment parameters between the treated groups with and without
HBO using the Student’s t-test or c2 test. Survival curves were
calculated using the Kaplan–Meier method (Kaplan and Meier,
1958). Differences between survival curves were determined using
the log-rank test (Mantel, 1966). The Cox proportional hazards
model was used to calculate the relative risk of each variable for
survival (Cox, 1972). Results were considered significant for
P-values < 0.05 and data were analysed using the SAS computer
software package (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
Twenty-nine patients were enrolled in the study (23 patients from
University Hospital of Occupational and Environmental Health
Table 1 Clinical characteristics of 29 patients with newly diagnosed
malignant glioma
Variables Treatment group Significance
With HBO (n = 15) Without HBO (n = 14)
Age at diagnosis (years)
Mean ± s.d. 55.5 ± 19.0 57.9 ± 6.8 NS
Gender
Male/female 8/7 9/5 NS
KPS score
60–70 8 4 NS
80–100 7 10
Mental status
Normal/abnormal 7/8 8/6 NS
Diagnosis procedure
Partial removal 9 13 0.082
Biopsy only 6 1
Histological category
Anaplastic astrocytoma 5 3 NS
Glioblastoma multiforme 10 11
Tumour location
Diencephalon 12 13
Thalamus 2 0 NS
Cerebellum 1 1
Radiation from symptom
(months)
Mean ± s.d. 2.7 ± 1.6 2.8 ± 1.4 NS
Radiation dose (Gy)
Mean ± s.d. 57.8 ± 5.7 58.7 ±3.7 NS
BED
Mean ± s.d. 71.5 ± 7.9 71.8 ± 3.9 NS
Other treatments
NU 12 10 NS
NU+FN 3 4
HBO: hyperbaric oxygenation, KPS: Karnofsky Performance Scale, BED:
biologically effective dose, NS: not significant, NU: nitrosourea, IFN:
interferon-b, P-values were determined using c2 test.238 K Kohshi et al
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and six from Amakusa Medical Center). Eleven and four patients
were treated by radiotherapy combined with HBO at the above two
institutions since 1991 and 1993 respectively. In July 1997, six
patients were still alive, with a median follow-up period of 37
months. The clinical characteristics of the treated patients are
summarized in Table 1. All patients were followed until death or
the completion of the study and were evaluated for response,
toxicity and survival. There were no differences between the two
treated groups in terms of patient characteristics and treatment
parameters. Biopsy surgery was performed more often in the
HBO-treated patients, but this was not statistically significant.
Twenty patients had a follow-up period of at least 9 months after
the completion of radiotherapy (range 2–76 months).
Response to therapy (Table 2)
Fifteen of the 29 patients responded during the follow-up periods.
Only three of these had a protracted or delayed response in which
continued to decrease in size for the ensuing 3–6 months. In the
non-HBO group, response to radiotherapy was seen in four of 14
patients (29%). All four responders showed partial regression at
the completion of the therapy, and one showed complete disap-
pearance of the tumour 4 months later. In the HBO group, 11 of 15
patients (73%) showed a partial or complete response to the
combined therapy, and nine of these showed a partial response at
the completion of the therapy. The other two responders did not
show more than 50% tumour regression at the completion of the
therapy, but they had a protracted or delayed response 6 months
later. Three responders showed complete disappearance of the
residual tumour 3–6 months later. All responders received irradia-
tion within 15 min after HBO exposure. Patients irradiated 30 min
after decompression had no tumour regression, but three of their
tumours remained stable for 11–14 months. The response rates
were significantly different between the two treated groups
(P < 0.05).
Survival analysis
In the non-HBO group, all four responders showed tumour recur-
rence. All 14 patients developed tumour growth or recurrence and
died within 36 months after diagnosis. In the HBO group, tumour
recurrence was seen in four of nine responders (two patients died
from causes unrelated to the tumour). Patient survival from diag-
nosis ranged from 4 to 78 months, with a median of 24 months. At
the time of this report, six patients were alive and three of them
were last evaluated at 78, 67 and 66 months, with the first two
patients having no evidence of recurrence. The histological type of
all these long-term survivors was anaplastic astrocytoma. The
median survival time for the HBO-treated group was 24 months
versus 12 months for the non-HBO treated group (mean follow-up
Table 2 Radiographic best response to treatment in 29 patients with newly
diagnosed malignant glioma
Treatment Response Response ratec Comparison ofd
group CR PR NR (%) response rate
With HBO 3a 8a 4b 73
(n = 15) P < 0.05
Without HBO 1 3 10 29
(n = 14)
HBO: hyperbaric oxygenation; CR: complete response, PR: partial response,
NR: no response; aIrradiated within 15 min after HBO, birradiated 30 min after
HBO, cresponse rates were calculated as the percentage of cases with
complete and partial responses, dresponse rates were compared using c2
test.
100
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Figure 1 Kaplan–Meier survival curve according to different schedules of
treatment: with or without HBO (hyperbaric oxygenation). The curves are
significantly different at P < 0.05
Table 3 Univariate analysis of prognostic variables for the survival of
patients
Variables Univariate
RR (95% CI) P-value
Age 1.046 1.004–1.089 0.0310
Gender 1.599 0.659–3.877 0.2995
KPS score 0.983 0.946–1.021 0.3768
Mental status 1.856 0.778–4.429 0.1636
Diagnosis procedure 0.935 0.274–3.195 0.9350
Histological category 5.581 1.584–19.660 0.0074
Tumour location 0.149 0.020–1.126 0.0651
Radiation from symptom 1.663 0.666–4.152 0.2758
Radiation dose 1.677 0.643–4.377 0.2907
BED 0.653 0.261–1.631 0.3614
Chemotherapeutic agents 0.709 0.252–1.993 0.5141
Treatment group 0.348 0.137–0.883 0.0264
RR: relative risk, 95% CI: 95% confidence interval, KPS: Karnofsky
performance scale, BED: biologically effective dose.
Table 4 Multivariate analysis of prognostic variables for the survival of
patients
Multivariate
Variables RR (95% CI) P-value
Age 1.050 0.985–1.119 0.1355
Histological category 4.482 0.954–21.063 0.0574
Tumour location 0.967 0.087–10.722 0.9784
Treatment group 0.266 0.088–0.800 0.0184
RR: relative risk, 95% CI: 95% confidence interval.Radiation after hyperbaric oxygen for malignant glioma 239
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was 26 and 16 months respectively). The differences between
survival curves and median survival time were significant
(P < 0.05) (Figure 1).
In a Cox model analysis to investigate the relationship between
prognostic factors and survival, univariate analysis showed that
histological grade and age significantly increased relative risks
(RR = 5.58, 95% CI: 1.584–19.660; RR = 1.05, 95% CI:
1.004–1.089 respectively), but the combined treatment signifi-
cantly increased survival rate as compared with treatment without
HBO (RR = 0.35, 95% CI: 0.137–0.883) (Table 3). When these
prognostic factors, including tumour location, were entered into a
multivariate analysis, the treatment group was the only significant
prognostic factor (RR = 0.27, 95% CI: 0.088–0.800) (Table 4).
Toxicity
As a side-effect of the chemotherapy, mild bone marrow suppres-
sion was noted in some patients, but it was not different in the two
groups. Moreover, radiation necrosis and convulsive seizures were
not seen in patients who received HBO. There were no other side-
effects regarding HBO exposure.
DISCUSSION
Our current pilot study shows that radiotherapy after HBO expo-
sure improved the survival of patients with malignant gliomas in
spite of the small number of patients and non-randomized investi-
gation. The data presented here indicate that the existence of
hypoxic tumour cells is important for radiotherapy of malignant
gliomas and that HBO acted as a radiosensitizer.
Tumour hypoxia
Tumour hypoxia in human malignant glioma has been studied by
direct and indirect measurements. In direct PO2 measurement with
a tube-type Clarke electrode, Kayama et al (1991) found that the
intratumoural PO2 value was significantly lower than that of the
surrounding brain. They also noted that there was no correlation
between intratumoural PO2 and tumour vascularity as demon-
strated on angiograms or CT scans. More recently, Rampling et al
(1994), using Eppendorf polarographic O2 electrode, revealed a
median PO2 value of 7.4 mm Hg in ten patients with glioblastoma
and the presence of a large amount of severely hypoxic cells
≤ 2.5 mmHg (9.5–68.5%). In contrast to these direct measure-
ments, identification of tumour hypoxia is very interesting in indi-
rect non-invasive methods using nuclear medical assays.
However, a definite tendency has not yet been established using
these methods. Groshar et al (1993) reported the results of single
photon emission computed tomography (SPECT) with [123I]iodo-
azomycin arabinoside in various histological tumours, but no
evidence for hypoxia was obtained in glioblastoma. However,
Valk et al (1992) showed increased uptake in two of three patients
with malignant gliomas using positron emission tomography
(PET) imaging of [18F]fluoromisonidazole. These different results
in SPECT and PET studies may be due to the differences of
imaging techniques and tracers (Rasey et al, 1996; Parliament et
al, 1997).
Tissue hypoxia generally occurs when the blood supply is inad-
equate to meet the demand. Because oxygen consumption is lower
in malignant gliomas than in the normal brain (Ito et al, 1982;
Tyler et al, 1987; Mineura et al, 1994), tumour hypoxia is induced
by low tumour blood flow. Radioresistance caused by hypoxia is
thought to develop by two major mechanisms: diffusion-limited
or chronic hypoxia, due to reduced oxygen diffusion to regions
distant from the tumour vessels (Thomlinson and Gray, 1955), and
acute hypoxia caused by transient occlusion of vessels (Chaplin
et al, 1986). In a recent study, Helmlinger et al (1997) measured
PO2 using a phosphorescence quenching microscopy technique in
human tumour xenografts, and reported that hypoxic (≤ 5 mmHg)
and near anoxic values (0–0.5 mmHg) were reached 70–80 and
³ 150 mm away from tumour vessels respectively. However, a few
histological studies on malignant gliomas have failed to obtain
a certain tendency of tumour vascular density (Yoshii and
Sugiyama, 1988; Stewart et al, 1991; Wesseling et al, 1994),
although blood flow is lower in malignant gliomas than in normal
white matter (Ito et al, 1982; Tyler et al, 1987; Mineura et al,
1994). These conflicting observations support the hypothesis that
tumour tissue perfusion is incomplete due to transient (acute
hypoxia) or partial occlusion of vessels (Chaplin et al, 1986). In
fact, tumour vessels of human glioma xenografts are not fully open
and the perfusion fraction of the vessels is relatively low, ranging
from 20 to 85% (mean: about 60%) (Bernsen et al, 1995).
Radiosensitivity of the tumour is well known to be determined
by the level of PO2, and to increase markedly by means of a very
small amount of oxygen (Gray et al, 1953; Hall, 1994). In the
present study, different tumour responses and survival rates
between the treated groups suggest that PO2 levels in malignant
gliomas remain elevated for a certain period after HBO exposure.
PO2 after HBO exposure
The changes of PO2 which respond to HBO exposure appear to be
entirely different between normal tissues and blood. Wells et al
(1977), using a mass spectrometer probe which quantified the
duration and magnitude of the HBO effect, found that tissue PO2
changed slowly during and after O2 inhalation at 2 atmospheres
absolute and that the decline in PO2 was slower in subcutaneous
tissue than in muscle. Moreover, they noted that the subcutaneous
tissue PO2 value was as much as 30% greater than the control
30 min after decompression. They concluded that the different
PO2 changes in tissues were partially due to differences in tissue
perfusion.
Many investigators have reported that metabolism in malignant
gliomas is anaerobic and that the oxygen consumption rate is
lower in the tumour than in normal white matter (Ito et al, 1982;
Tyler et al, 1987; Mineura et al, 1994). Normal brain PO2 has been
noted to decrease quickly after HBO exposure in animal experi-
ments (Jamieson and van den Brenk, 1963). PO2 in malignant
gliomas declines more slowly after decompression due to low
oxygen consumption in addition to low blood flow. We postulated
that only tumour PO2 remains elevated for a substantial period
after decompression. According to this hypothesis, radiotherapy
after HBO exposure may increase the sensitivity of hypoxic
tumour cells without an increase in normal brain injury. From our
small series, this new combined treatment appears to be very
effective for patients with malignant gliomas (Kohshi et al, 1996).
However, the present result that no cases irradiated 30 min after
decompression had tumour regression, suggests that the tumour
PO2 may decrease in the period between 15 and 30 min after HBO
exposure to lower levels without enhancing the effect of radio-
therapy. The tumour PO2 change after HBO exposure is a very
important subject for future study.Radiation during HBO exposure
Many clinical trials have been performed in cancer treatments of
radiotherapy combined with HBO. The previous combined
method was a repetitive administration of irradiation during HBO
exposure. In some clinical trials, significant improvements in local
control and survival have been seen in cancers of head and neck,
cervical region and uterine cervix (Henk et al, 1977; Watson et al,
1978; Henk, 1986), but no benefit has been demonstrated in
patients with cancers of skin, bronchus and bladder (Sealy et al,
1974; Cade and McEwen, 1978). There are only two reports of
human malignant gliomas treated with this therapeutic method
(Chang, 1977; Dowling et al, 1992). One of them showed that the
median survival rate at 18 months appeared considerably higher in
the HBO group (28%) than in the control (10%) (Chang, 1977).
Two of 38 patients who received HBO lived more than 4 years.
One patient who died from radiation necrosis of the brain was
identified as having no microscopic evidence of residual tumour.
Irradiation during HBO exposure had been recognized as a
promising therapeutic method for treating malignant gliomas. For
this regimen, however, irradiating in a pressure chamber required
sedation before each irradiation and myringotomies (Chang,
1977). The irradiated region was the whole brain and it was diffi-
cult to reduce the local area to the tumour field. Unfortunately,
serious side-effects, such as radiation necrosis and convulsive
seizures, were induced in some patients (Chang, 1977; Jain, 1990).
Therefore, this regimen has not been used as a standard treatment
for malignant gliomas (Jain, 1990; Dische, 1991).
Radiation after HBO exposure
Our new therapeutic regimen, irradiating after HBO exposure, is
very simple and safe for the patients so myringotomy and sedation
are not required. The combination with HBO produced a signifi-
cant reduction of residual tumour, and a response was seen in all
patients irradiated immediately after decompression. In studies
assessed radiographically, patients who responded to radiotherapy
tended to live longer than non-responders (Murovic et al, 1986;
Wood et al, 1988; Barker et al, 1996). Although our series repre-
sents non-randomized data in a small number of patients, the
treated groups did not differ substantially. Nevertheless, we signif-
icantly prolonged the survival time in the HBO group. Prognostic
factors in malignant gliomas are generally well known to be
histology, age, KPS, prior surgery, mental status and time from
first symptom (Burger and Green, 1987; Curran et al, 1993).
Multivariate analysis in our small series revealed that combination
with HBO was a good predictive prognostic factor for survival.
Radiotherapy after HBO exposure is one of the initial treatment
options for patients with malignant gliomas. However, all four
patients irradiated 30 min after decompression showed no tumour
regression and died due to tumour growth. The timing of irradia-
tion may be very important in this regimen and irradiation should
be done immediately after HBO exposure in order to improve the
therapeutic effects.
The results of this trial suggest that HBO can increase the effi-
cacy of radiotherapy in malignant gliomas. In order to provide
more convincing evidence of this, randomized clinical trials must
be undertaken.
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